 Intercept Pharmaceuticals Inc on Monday released additional results of a closely watched clinical trial suggesting that an experimental liverdisease drug may have had a more benign effect on patients cholesterol levels than initially thought  The new study detailswhich Intercept disclosed in a securities filing and on a conference call with analystssparked a nearly  surge in Intercepts stock price in afterhours trading Monday to  after closing at  Analysts believe the drug has multibilliondollar
  